Safety and efficacy of 12 weeks of sofosbuvir plus daclatasvir for Chinese refractory hepatitis C patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15007449

Enrollment

Unknown

Registered

2015-05-01

Start date

2015-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

A:sofosbuvir/daclatasvir/ribavirin

B:??????????????

C:sofosbuvir/daclatasvir

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. CHC patients; 2. Interferontreatment-experienced (treatment failure); 3. Aged 18-70 years.

Exclusion criteria

Exclusion criteria: 1. Patients infected wiht HBV; 2. Patients infected wiht HIV; 3. Patients infected wiht systematic disorders.

Design outcomes

Primary

Measure	Time frame
HCV RNA;	—

Countries

China

Contacts

Public ContactZu-Jiang Yu

zengqinglei2009@163.com+86 15838120512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026